HVO.L

Equity

HVIVO PLC ORD 0.1P

Health Care · Diagnostics & Research

$7.90

+7.90 (+0.00%)

Open

N/A

Day Range

$7.90 - $8.30

52W Range

$4.31 - $19.50

Volume

1M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Is It Time To Reassess Box (BOX) After Its Recent Share Price Weakness

Simply Wall St. 1 day ago

Is NVR (NVR) Still Attractive After Recent Share Price Pause?

Simply Wall St. 1 day ago

Is Moncler (BIT:MONC) Pricing In Too Much Optimism After Its Recent Share Rebound

Simply Wall St. 1 day ago

Fair Value Estimate

DDM Value

$4.20

88.1% overvalued

Growth: 5.0% | Req. return: 10%

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ACB Aurora Cannabis Inc. $3.71 N/A - +0.00%
AKBA Akebia Therapeutics, Inc. $1.26 N/A - +0.00%
ABCL AbCellera Biologics Inc. $3.74 N/A - +0.00%
ACAD ACADIA Pharmaceuticals Inc. $22.81 N/A - +0.00%
001540.KQ AHN-GOOK PHA $7,870.00 N/A 5.59% +0.00%
A Agilent Technologies, Inc. $116.88 N/A 0.85% +0.00%
ABBV AbbVie Inc. $234.26 N/A 2.84% +0.00%
ABT Abbott Laboratories $114.12 N/A 2.10% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About HVIVO PLC ORD 0.1P

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD. In addition, the company offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, it provides pre­clinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company offers services to big pharma and biotech organizations. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

www.hvivo.com →

🐂 Bull Score

Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.

F 16/100

Very Risky

Bull Score

~ Short dividend streak (1 years) 5/25
+ Good profit margin (17%) 11/15
Limited data — score may change as more metrics become available

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

60

Safe

Based on 4 fundamental factors

~ Recent dividend growth (1 yr)
~ Decent profit margins (17%)

Analysis Tools

Sign in for analysis tools

Share